Gd-EOB-DTPA enhanced MRI nomogram model to differentiate hepatocellular carcinoma and focal nodular hyperplasia both showing iso- or hyperintensity in the hepatobiliary phase.
Humans
Carcinoma, Hepatocellular
/ diagnostic imaging
Gadolinium DTPA
Liver Neoplasms
/ diagnostic imaging
Female
Male
Nomograms
Focal Nodular Hyperplasia
/ diagnostic imaging
Middle Aged
Magnetic Resonance Imaging
/ methods
Diagnosis, Differential
Contrast Media
Adult
Aged
Retrospective Studies
ROC Curve
Carcinoma
Focal nodular hyperplasia
Hepatocellular
Magnetic resonance imaging
Nomogram
Journal
BMC medical imaging
ISSN: 1471-2342
Titre abrégé: BMC Med Imaging
Pays: England
ID NLM: 100968553
Informations de publication
Date de publication:
12 Aug 2024
12 Aug 2024
Historique:
received:
01
05
2024
accepted:
29
07
2024
medline:
13
8
2024
pubmed:
13
8
2024
entrez:
12
8
2024
Statut:
epublish
Résumé
To develop and validate a nomogram model based on Gd-EOB-DTPA enhanced MRI for differentiation between hepatocellular carcinoma (HCC) and focal nodular hyperplasia (FNH) showing iso- or hyperintensity in the hepatobiliary phase (HBP). A total of 75 patients with 49 HCCs and 26 FNHs randomly divided into a training cohort (n = 52: 34 HCC; 18 FNH) and an internal validation cohort (n = 23: 15 HCC; 8 FNH). A total of 37 patients (n = 37: 25 HCC; 12 FNH) acted as an external test cohort. The clinical and imaging characteristics between HCC and FNH groups in the training cohort were compared. The statistically significant parameters were included into the FAE software, and a multivariate logistic regression classifier was used to identify independent predictors and establish a nomogram model. Receiver operating characteristic (ROC) curves were used to evaluate the prediction ability of the model, while the calibration and decision curves were used for model validation. Subanalysis was used to compare qualitative and quantitative characteristics of patients with chronic hepatitis and cirrhosis between the HCC and FNH groups. In the training cohort, gender, age, enhancement rate in the arterial phase (AP), focal defects in uptake were significant predictors for HCC showing iso- or hyperintensity in the HBP. In the training cohort, area under the curve (AUC), sensitivity and specificity of the nomogram model were 0.989(95%CI: 0.967-1.000), 97.1% and 94.4%. In the internal validation cohort, the above three indicators were 0.917(95%CI: 0.782-1.000), 93.3% and 87.5%. In the external test cohort, the above three indicators were 0.960(95%CI: 0.905-1.000), 84.0% and 100.0%. The results of subanalysis showed that age was the independent predictor in the patients with chronic hepatitis and cirrhosis between HCC and FNH groups. Gd-EOB-DTPA enhanced MRI nomogram model may be useful for discriminating HCC and FNH showing iso- or hyperintensity in the HBP before surgery.
Sections du résumé
BACKGROUND
BACKGROUND
To develop and validate a nomogram model based on Gd-EOB-DTPA enhanced MRI for differentiation between hepatocellular carcinoma (HCC) and focal nodular hyperplasia (FNH) showing iso- or hyperintensity in the hepatobiliary phase (HBP).
METHODS
METHODS
A total of 75 patients with 49 HCCs and 26 FNHs randomly divided into a training cohort (n = 52: 34 HCC; 18 FNH) and an internal validation cohort (n = 23: 15 HCC; 8 FNH). A total of 37 patients (n = 37: 25 HCC; 12 FNH) acted as an external test cohort. The clinical and imaging characteristics between HCC and FNH groups in the training cohort were compared. The statistically significant parameters were included into the FAE software, and a multivariate logistic regression classifier was used to identify independent predictors and establish a nomogram model. Receiver operating characteristic (ROC) curves were used to evaluate the prediction ability of the model, while the calibration and decision curves were used for model validation. Subanalysis was used to compare qualitative and quantitative characteristics of patients with chronic hepatitis and cirrhosis between the HCC and FNH groups.
RESULTS
RESULTS
In the training cohort, gender, age, enhancement rate in the arterial phase (AP), focal defects in uptake were significant predictors for HCC showing iso- or hyperintensity in the HBP. In the training cohort, area under the curve (AUC), sensitivity and specificity of the nomogram model were 0.989(95%CI: 0.967-1.000), 97.1% and 94.4%. In the internal validation cohort, the above three indicators were 0.917(95%CI: 0.782-1.000), 93.3% and 87.5%. In the external test cohort, the above three indicators were 0.960(95%CI: 0.905-1.000), 84.0% and 100.0%. The results of subanalysis showed that age was the independent predictor in the patients with chronic hepatitis and cirrhosis between HCC and FNH groups.
CONCLUSIONS
CONCLUSIONS
Gd-EOB-DTPA enhanced MRI nomogram model may be useful for discriminating HCC and FNH showing iso- or hyperintensity in the HBP before surgery.
Identifiants
pubmed: 39134943
doi: 10.1186/s12880-024-01382-6
pii: 10.1186/s12880-024-01382-6
doi:
Substances chimiques
Gadolinium DTPA
K2I13DR72L
gadolinium ethoxybenzyl DTPA
0
Contrast Media
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
211Informations de copyright
© 2024. The Author(s).
Références
Sweed D, Sweed E, Moaz I, et al. The clinicopathological and prognostic factors of hepatocellular carcinoma: a 10-year tertiary center experience in Egypt. World J Surg Oncol. 2022;20(1):298.
doi: 10.1186/s12957-022-02764-2
pubmed: 36117166
pmcid: 9484175
Zhang CH, Cheng Y, Zhang S, Fan J, Gao Q. Changing epidemiology of hepatocellular carcinoma in Asia. Liver Int. 2022;42(9):2029–41.
doi: 10.1111/liv.15251
pubmed: 35319165
Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1–61.
doi: 10.1016/bs.acr.2020.10.001
pubmed: 33579421
Raatschen HJ. Radiological diagnostic workup of liver tumors. Internist (Berl). 2020;61(2):123–30.
doi: 10.1007/s00108-019-00724-9
pubmed: 31919534
Oldhafer KJ, Habbel V, Horling K, et al. Benign liver tumors. Visc Med. 2020;36(4):292–303.
pubmed: 33005655
LeGout JD, Bolan CW, Bowman AW, et al. Focal nodular Hyperplasia and focal nodular hyperplasia-like lesions. Radiographics. 2022;42(4):1043–61.
doi: 10.1148/rg.210156
pubmed: 35687520
Kawada N, Ohkawa K, Tanaka S, et al. Improved diagnosis of well-differentiated hepatocellular carcinoma with gadolinium ethoxybenzyl diethylene triamine pentaacetic acid-enhanced magnetic resonance imaging and Sonazoid contrast-enhanced ultrasonography. Hepatol Res. 2010;40(9):930–6.
doi: 10.1111/j.1872-034X.2010.00697.x
pubmed: 20887598
Nie P, Yang G, Guo J, et al. A CT-based radiomics nomogram for differentiation of focal nodular hyperplasia from hepatocellular carcinoma in the non-cirrhotic liver. Cancer Imaging. 2020;20(1):20.
doi: 10.1186/s40644-020-00297-z
pubmed: 32093786
pmcid: 7041197
Ding Z, Lin K, Fu J, et al. An MR-based radiomics model for differentiation between hepatocellular carcinoma and focal nodular hyperplasia in non-cirrhotic liver. World J Surg Oncol. 2021;19(1):181.
doi: 10.1186/s12957-021-02266-7
pubmed: 34154624
pmcid: 8215802
Li W, Li R, Zhao X, et al. Differentiation of Hepatocellular Carcinoma from Hepatic Hemangioma and focal nodular hyperplasia using computed Tomographic Spectral Imaging. J Clin Transl Hepatol. 2021;9(3):315–23.
pubmed: 34221917
pmcid: 8237149
Hanaoka J, Shimada M, Utsunomiya T, et al. Huge focal nodular hyperplasia difficult to distinguish from well-differentiated hepatocellular carcinoma. Hepatol Res. 2012;42(7):727–31.
doi: 10.1111/j.1872-034X.2012.00974.x
pubmed: 22686861
Lee MH, Kim SH, Park MJ, et al. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease. AJR Am J Roentgenol. 2011;197(5):W868–875.
doi: 10.2214/AJR.10.6237
pubmed: 22021534
Kitao A, Zen Y, Matsui O, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR imaging–correlation with molecular transporters and histopathologic features. Radiology. 2010;256(3):817–26.
doi: 10.1148/radiol.10092214
pubmed: 20663969
Zech CJ, Grazioli L, Breuer J, Reiser MF, Schoenberg SO. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol. 2008;43:504–11.
doi: 10.1097/RLI.0b013e3181705cd1
pubmed: 18580333
Chernyak V, Fowler KJ, Kamaya A, et al. Liver Imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology. 2018;289:816–30.
Vernuccio F, Gagliano DS, Cannella R, Ba-Ssalamah A, Tang A, Brancatelli G. Spectrum of liver lesions hyperintense on hepatobiliary phase: an approach by clinical setting. Insights Imaging. 2021;12(1):8.
doi: 10.1186/s13244-020-00928-w
pubmed: 33432491
pmcid: 7801550
Khanna M, Ramanathan S, Fasih N, Schieda N, Virmani V, McInnes MD. Current updates on the molecular genetics and magnetic resonance imaging of focal nodular hyperplasia and hepatocellular adenoma. Insights Imaging. 2015;6:347–62.
doi: 10.1007/s13244-015-0399-8
pubmed: 25790815
pmcid: 4444792
Wu J, Zhang H, Li L, et al. A nomogram for predicting overall survival in patients with low-grade endometrial stromal sarcoma: a population-based analysis. Cancer Commun (Lond). 2020;40(7):301–12.
doi: 10.1002/cac2.12067
pubmed: 32558385
Kong C, Zhao Z, Chen W, et al. Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE. Eur Radiol. 2021;31(10):7500–11.
doi: 10.1007/s00330-021-07910-0
pubmed: 33860832
pmcid: 8452577
Wang Q, Qiao W, Zhang H, et al. Nomogram established on account of Lasso-Cox regression for predicting recurrence in patients with early-stage hepatocellular carcinoma. Front Immunol. 2022;13:1019638.
doi: 10.3389/fimmu.2022.1019638
pubmed: 36505501
pmcid: 9726717
Kitao A, Matsui O, Yoneda N, et al. Differentiation between hepatocellular carcinoma showing hyperintensity on the hepatobiliary phase of Gadoxetic acid-enhanced MRI and focal nodular hyperplasia by CT and MRI. AJR Am J Roentgenol. 2018;211:347–57.
doi: 10.2214/AJR.17.19341
pubmed: 29708786